We have surveyed 500+ Life Sciences executives from over 160 biopharma companies in 7 countries to identify the most significant challenges and barriers to maturity in developing a connected health portfolio. We also set out to understand the strategic objectives of biopharma companies and the governance structures required to support connected health, as well as to pinpoint the values and benefits that connected health products can bring to biopharma companies.